Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

Rhea-AI Summary

Adial Pharmaceuticals, based in Charlottesville, Va., announces that Cary Claiborne, CEO, will present at the 35th Annual Roth Conference on March 14, 2023. The event takes place at The Ritz Carlton, Laguna Niguel in Dana Point, California, and Claiborne's presentation is scheduled for 12:00 PM PT. Investors can access a live audio webcast of the presentation via this link. Adial focuses on developing therapies for addiction; its lead drug AD04 targets Alcohol Use Disorder with promising results from its Phase 3 trial.

CHARLOTTESVILLE, Va., March 08, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that Cary Claiborne, President and Chief Executive Officer of Adial, will be presenting at the 35^th Annual Roth Conference being held March 13 - 14, 2023 at The Ritz Carlton, Laguna Niguel located in Dana Point, California.

Event	35th Annual Roth Conference
Date	March 14, 2023
Presentation	12:00 PM Pacific Time (3:00 PM Eastern Time)
Webcast	https://wsw.com/webcast/roth46/adil/1802710
Location	Dana Point, CA

The live audio webcast and replay will be available in the investor relations section of the Company’s website at www.adial.com/news-events/.

Mr. Claiborne will be available for one-on-one and small group investor meetings during the conference.

To arrange a 1-on-1 please email oneononerequests@roth.com, or contact your Roth sales team. For more information about the event or questions about registration, please contact your Roth representative.

About Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes (estimated to be approximately one-third of the AUD population) identified using the Company’s companion diagnostic genetic test. ONWARD showed promising results in reducing heavy drinking in heavy drinking patients, and no overt safety or tolerability concerns. AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. Additional information is available at www.adial.com.

Contact:
Crescendo Communications, LLC                        
David Waldman / Alexandra Schilt                        
Tel: 212-671-1020                                
Email: adil@crescendo-ir.com

FAQ

What is the date of the 35th Annual Roth Conference where Adial will present?

The 35th Annual Roth Conference will be held on March 14, 2023.

What time will Adial Pharmaceuticals' presentation occur at the Roth Conference?

Adial Pharmaceuticals' presentation is scheduled for 12:00 PM Pacific Time (3:00 PM Eastern Time).

How can I watch the Adial presentation at the Roth Conference?

The presentation can be accessed via a live audio webcast at this link: https://wsw.com/webcast/roth46/adil/1802710.

What is the focus of Adial Pharmaceuticals?

Adial Pharmaceuticals is focused on developing therapies for addiction and related disorders.

What is AD04 and its significance for Adial Pharmaceuticals?

AD04 is Adial's lead drug targeting Alcohol Use Disorder, showing promising results in reducing heavy drinking in clinical trials.